• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence

    1/23/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    BURLINGTON, Mass., Jan. 23, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of internationally significant sample collections. This new system is in addition to the seven Azenta BioArc™ Flex™ automated sample store systems already in place at the facility. UK Biocentre will utilize the new BioArc Ultra™ to deliver on critical research projects including the United Kingdom's largest health research program – Our Future Health.

    The BioArc Ultra will be installed into UK Biocentre's 70,000 square-foot facility in Milton Keynes, England, which specializes in the management and processing of biological samples. Currently capable of storing over 35 million samples, the facility will expand its capacity to conduct large-scale biomedical research by an additional 16 million samples with BioArc Ultra's high-density, fully automated -80°C storage system with picking capability of up to 9 million picks per year. As part of the overall solution, UK Biocentre utilizes Azenta's automated systems, as well as FluidX™ 2D-coded, high-quality screw-cap tubes, to elevate inventory management quality, reduce variability, and mitigate risk for this and other vital research projects.

    The Ultra delivers significant operational efficiency benefits, including reduced footprint, labor requirements, and electricity costs as compared to other commercially available systems, and benefits UK Biocentre's carbon emission reduction goals through the use of an eco-friendly refrigeration system with zero Ozone Depletion Potential and zero Global Warming Potential, thus advancing sustainability in science. This robust automation system offers the option of up to 10 picking stations, providing the flexibility to increase throughput and/or labware types.

    UK Biocentre will utilize the storage capacity of the BioArc Ultra in support of the UK's Our Future Health study of up to 5 million people in the development of new ways to prevent, detect, and treat diseases.

    Dr. Tony Cox OBE, Chief Executive Officer of UK Biocentre, stated, "The BioArc Ultra ensures UK Biocentre remains at the forefront of large-scale sample storage innovation while fulfilling our mission to reduce the environmental impact of vital clinical and life science research. We are proud to partner with Azenta Life Sciences to bring this unique offering to the UK, enabling us to maximize the potential of every sample."

    "We are excited to support UK Biocentre with the advanced automation sample storage capabilities of the BioArc Ultra," said Alex Esmon, Vice President and General Manager of Global Products at Azenta Life Sciences. "The addition of the BioArc Ultra delivers on the promise of enabling breakthroughs faster through substantial improvements in proven automation and refrigeration technology that ensures critical sample integrity while streamlining workflows and ensuring sustainability."

    To learn more about the BioArc Ultra, visit https://www.azenta.com/products/bioarc-ultra-high-density-80-c-automated-sample-storage-system.

    About Azenta Life Sciences

    Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

    Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

    About the UK Biocentre

    UK Biocentre is a respected leader in sample management, high-capacity bioprocessing & analysis, and automated storage. We support and facilitate large-scale biomedical, pharmaceutical, and clinical studies, enabling life-changing research in the academic, pharmaceutical and biotech communities. From the outset we've valued our role as essential collaborators in the scientific process providing reliable, high-quality solutions that help researchers make critical advancements in their fields. This drives our passion for delivering unparalleled services, using state-of-the-art technology, and adhering to the highest compliance, certification, and accreditation standards. For more information, please visit www.ukbiocentre.com.

    INVESTOR CONTACTS:

    Yvonne Perron

    Vice President, Financial, Planning & Analysis and Investor Relations

    [email protected]

    PUBLIC RELATIONS CONTACT:

    Renay Picard

    Director of Marketing, Sample Management Solutions

    [email protected]

    Azenta logo (PRNewsfoto/Azenta)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/uk-biocentre-selects-the-azenta-life-sciences-bioarc-ultra-automated-storage-system-to-advance-research-excellence-302359087.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    1/5/2026$50.00In-line → Outperform
    Evercore ISI
    12/19/2025$42.00 → $44.00Buy
    Needham
    10/30/2025$38.00Hold → Buy
    Jefferies
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    7/22/2025$35.00Equal-Weight
    Stephens
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Cornog William L bought $189,884 worth of Common (7,000 units at $27.13), increasing direct ownership by 37% to 25,795 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/25/25 4:28:43 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: Director Malus Alan J bought $319,800 worth of Common (12,000 units at $26.65), increasing direct ownership by 238% to 17,035 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:07 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: President and CEO Marotta John bought $25,990 worth of Common (1,000 units at $25.99), increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:08 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

    BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

    3/4/26 9:11:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference

    BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta p

    2/24/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure

    BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate discovery and innovation in life sciences, including participation in the recently launched EGGS-2 (Early Gen micro-Gravity Service) mission, developed in collaboration with Orbital Paradigm. The mission was intended to test and advance the performance of Frontier's SpaceLab Mk 2 research platform under real launch and spaceflight conditions. This co

    2/9/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Cornog William L

    4/A - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:21:57 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Director Nova Tina Susan was granted 5,663 units of Common, increasing direct ownership by 56% to 15,772 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:12:14 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Cornog William L

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 5:47:58 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Azenta from In-line to Outperform and set a new price target of $50.00

    1/5/26 8:28:55 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Needham reiterated coverage on Azenta with a new price target

    Needham reiterated coverage of Azenta with a rating of Buy and set a new price target of $44.00 from $42.00 previously

    12/19/25 7:47:35 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Jefferies with a new price target

    Jefferies upgraded Azenta from Hold to Buy and set a new price target of $38.00

    10/30/25 7:56:09 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    SEC Filings

    View All

    Azenta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    3/4/26 9:15:52 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form 10-Q filed by Azenta Inc.

    10-Q - Azenta, Inc. (0000933974) (Filer)

    2/5/26 4:09:16 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    2/4/26 7:24:14 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Financials

    Live finance-specific insights

    View All

    Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

    BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

    3/4/26 9:11:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025

    BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ

    2/4/26 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

    BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

    1/21/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    View All

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

    Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

    9/4/24 8:00:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13D/A filed by Azenta Inc.

    SC 13D/A - Azenta, Inc. (0000933974) (Subject)

    11/4/24 8:41:47 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Azenta Inc.

    SC 13G - Azenta, Inc. (0000933974) (Subject)

    10/31/24 11:55:02 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology